Cowen analyst Ritu Baral reiterated an Outperform rating on Avidity Biosciences (NASDAQ: RNA), following the company's Q4 report. The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE